Gilligan D M, Dan D
Department of Internal Medicine, Hunter Holmes McGuire Veterans Affairs Medical Center and Medical College of Virginia/Virginia Commonwealth University, Richmond 23249, USA.
Lasers Med Sci. 2001;16(2):113-21. doi: 10.1007/pl00011340.
Pacing and defibrillation leads may need to be removed for several reasons including infection, interference with others leads, lack of vascular access or redundancy. However, the removal of chronically implanted leads is a major technical challenge because of the extensive adhesions that develop along the course of the leads over time. The techniques to remove chronic leads have been greatly facilitated by the development of an excimer laser sheath. We undertook an analysis of our experience with laser extraction in the first 50 leads attempted. An excimer laser sheath system, developed by the Spectranetics Corporation, was used to extract 50 chronically implanted leads in 34 patients. The mean patient age was 64+/-12 years, all were male and the average duration that the leads had been implanted was 5.0+/-3.9 years. Two-thirds of the leads were pacemaker and one-third were defibrillator leads. There was a 100% clinical success rate and 48 of the 50 leads were completely removed. There were no major complications. There was one minor complication of subclavian vein thrombosis and two haemodynamically non-significant episodes of air embolism. The main limitation observed was failure of the excimer laser sheath to advance in 18% of cases, probably due to the presence of calcified adherences on leads. Two strategies were found useful to deal with this problem: under the clavicle stainless-steel sheaths were used to break up calcified adherences and within the venous system the laser sheath was upsized in order to advance over the calcification on the lead. It was concluded that excimer laser has greatly facilitated the removal of chronically implanted pacemaker and defibrillator leads. There is a high success rate and low complication rate in our experience. The main limitation of laser is the presence of calcified adherences.
由于多种原因,如感染、干扰其他导联、缺乏血管通路或冗余等,可能需要移除起搏和除颤导线。然而,由于随着时间的推移导线周围会形成广泛粘连,移除长期植入的导线是一项重大技术挑战。准分子激光鞘管的发展极大地促进了慢性导线移除技术的发展。我们对最初尝试的50根导线进行激光拔除的经验进行了分析。使用光谱医疗公司开发的准分子激光鞘管系统,为34例患者拔除了50根长期植入的导线。患者平均年龄为64±12岁,均为男性,导线平均植入时间为5.0±3.9年。三分之二的导线为起搏器导线,三分之一为除颤器导线。临床成功率为100%,50根导线中有48根被完全移除。无重大并发症。有1例锁骨下静脉血栓形成的轻微并发症和2例血流动力学上无显著意义的空气栓塞事件。观察到的主要局限性是准分子激光鞘管在18%的病例中无法推进,可能是由于导线上存在钙化粘连。发现两种策略有助于解决这个问题:在锁骨下使用不锈钢鞘管来分解钙化粘连,在静脉系统内增大激光鞘管尺寸以便越过导线上的钙化部分。得出的结论是,准分子激光极大地促进了长期植入的起搏器和除颤器导线的移除。根据我们的经验,成功率高且并发症发生率低。激光的主要局限性是存在钙化粘连。